A Short-term Clinical Study Of Different Dose Of Bortezomib And Dexamethasone For The Treatment Of Multiple Myeloma

Objective To discuss the appropriate dose of bortezomib for treatment of patients with multiple myeloma(MM)by evaluating the curative effects and toxicity of two different doses of bortezomib(1.3mg/m~2 and 1.6mg/m~2). Method Twenty-five patients received two different doses of bortezomib from June 2013 to June 2014.With 15 receiving a dose of 1.3mg/m~2 and the other 9 receiving a dose of 1.6mg/m~2.The curative effects and the adverse events were observed. Results(1)After the second courses,two patients were CR in group of 1.3mg/m~2,the rate was 13.3%,the ORR of 1.3mg/m~2 group was 73.3%.One patient was CR in group of 1.6mg/m~2,the rate was 11.1%,the ORR of 1.6mg/m~2 group was 66.7%.There wasn’t a significant difference between two group(P>0.05).(2)After the forth courses,six patients were CR in group of 1.3mg/m~2,the rate was 40.0%,the ORR of 1.3mg/m~2 was 87.6%.Three patients were CR in group of 1.6mg/m~2,the rate was 33.3%,the ORR of 1.6mg/m~2 was 77.8%.There wasn’t a significant difference between two groups(P>0.05).(3)The adverse events included gastrointestinal symptoms,peripheral neuropathy,hematologic toxicity,infection and so on.The incident rate in 1.3mg/m~2 group was 40.0%,26.7%,20% and 13.3%,while it was 55.6%,22.2%,11.1% and 11.1% in 1.6mg/ m~2 group.There was no significant difference(P>0.05). Conclusion Comparing with the traditional use of bortezomib,the 1.6mg/m~2 group has the same curative effect,and there wasn’t aggravated adverse events.